Neurim Pharmaceuticals LTD

Circadin is Approved in the EU for Treatment of Primary Insomnia in Patients Aged 55 or Over for up to 3 Months

Circadin(R) - Prolonged Release Melatonin for Primary Insomnia is Licensed to Sigma Pharmaceuticals for Australia Markets

Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients

TEL AVIV, Israel, July 5, 2010 - Neurim Pharmaceuticals (www.Neurim.com) confirmed today that the European Commission (EC) has approved a change in treatment duration with Circadin from 3 to 13 weeks (3 months).

MORE..

TEL AVIV, Israel, December 14 - Sigma Pharmaceuticals Ltd.

MORE..

Older News

SEATTLE - Neurim Pharmaceuticals (www.neurim.com) presented today the preliminary results of a large-scale Phase III study of Circadin(R) 2mg, prolonged release melatonin in insomnia, demonstrating long term efficacy and safety in elderly patients.

MORE..